Lilly has announced an important change to its data collection practices regarding the 340B drug pricing program, which is designed to provide discounted medications to vulnerable patients. Starting January 15, Lilly will extend its collection of claims data to all pharmacy purchases. This move aims to combat fraud and abuse within the program, ensuring that the lower prices benefit patients rather than being exploited by hospitals and their for-profit partners.

This change is particularly relevant for people who rely on the 340B program for affordable medications. By collecting more comprehensive data, Lilly hopes to prevent misuse that ultimately harms patients and taxpayers. The goal is to enhance compliance and transparency, making sure that the program serves its intended purpose of helping those in need. This is crucial for maintaining the integrity of the 340B program, which is meant to support vulnerable populations.

Lilly’s decision is backed by decades of federal guidance and court rulings that affirm the legality of collecting such claims data. The company emphasizes that this new data collection will not impose additional burdens on hospitals, as it uses existing data that they already gather. However, the American Hospital Association has criticized this change, alleging it is illegal and burdensome, which Lilly disputes. The company urges the AHA to prioritize patient welfare over profit motives.

In summary, Lilly’s updated claims data collection aims to strengthen the 340B program, ensuring that discounted medications reach those who need them most while reducing the potential for abuse.

Source: investor.lilly.com